Iterum Therapeutics plc (ITRM) financial statements (2021 and earlier)

Company profile

Business Address BLOCK 2 FLOOR 3, HARCOURT CENTRE
DUBLIN, 2
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15585
Cash and cash equivalents15545
Short-term investments  40
Restricted cash and investments000
Receivables000
Prepaid expense111
Deferred costs 2 
Other undisclosed current assets647
Total current assets:211293
Noncurrent Assets
Property, plant and equipment011
Restricted cash and investments000
Other noncurrent assets11134
Total noncurrent assets:11145
TOTAL ASSETS:332698
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32811
Accounts payable1154
Accrued liabilities2127
Taxes payable000
Debt661
Derivative instruments and hedges, liabilities29  
Other liabilities43 
Other undisclosed current liabilities0  
Total current liabilities:423712
Noncurrent Liabilities
Long-term debt and lease obligation28813
Long-term debt, excluding current maturities22813
Operating lease, liability5 
Liabilities, other than long-term debt671
Other liabilities671
Other undisclosed noncurrent liabilities8  
Total noncurrent liabilities:421514
Total liabilities:835226
Stockholders' equity
Stockholders' equity attributable to parent(51)(26)72
Common stock000
Additional paid in capital236209203
Accumulated deficit(287)(235)(132)
Total stockholders' equity:(51)(26)72
TOTAL LIABILITIES AND EQUITY:332698

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit: 01
Operating expenses(32)(102)(77)
Operating loss:(32)(102)(77)
Nonoperating expense(19)(1)(0)
Other nonoperating income000
Interest and debt expense0  
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)  
Loss from continuing operations before income taxes:(51)(103)(77)
Income tax expense(1)(0)(0)
Net loss available to common stockholders, diluted:(52)(103)(77)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(52)(103)(77)
Comprehensive loss, net of tax, attributable to parent:(52)(103)(77)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: